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Phosphatases are important in signal transduction, 
bacterial pathogenesis and several human diseases. So 
far, however, it is their opposite numbers, the kinases, 
that have received more attention from chemists. 
Recent progress in inhibitor development offers hope 
that new probes of cellular processes, and perhaps 
novel therapeutic agents, may soon become available. 
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Energy utilization, signal transduction, transcription, trans- 
lation, DNA replication, and phospholipid metabolism are 
just a few of the varied biological processes that rely on 
phosphor+group transfer reactions. Kinases and phos- 
phatases are two classes of enzymes that exemplify the bio- 
chemistry of phosphoryl-group transfer. Kinases catalyze 
the synthesis of phosphate esters from ATP and a phos- 
phoryl-group acceptor, while phosphatases catalyze the 
hydrolysis of phosphate esters: 
RO-P0,2- 
Phosphatase 1 
-f? RoH 
ADP ATP 
(1) 
Because of their importance in cell transformation, 
protein kinases have attracted the lion’s share of attention 
from researchers seeking new methods to attack neoplas- 
tic disorders. But phosphatases, especially those that act 
on protein phosphates, may be equally useful targets in 
the search for new therapeutics. Phosphatases are essen- 
tial for the growth or virulence of a number of pathogenic 
organisms, such as bacteria of the Saftnonella and Yersinia 
families (including those responsible for bubonic plague) 
and viruses such as Vaccinia and Variola (which cause pox 
illnesses, such as smallpox) [l]. The serine/threonine 
phosphatase calcineurin is the target of immunosuppres- 
sants such as cyclosporin A and FK506 [2]. In addition, 
the importance of phosphatases in signal transduction and 
cell metabolism suggests that phosphatases may be 
appropriate therapeutic targets for disorders as diverse as 
diabetes and cancer. 
As attention becomes focused on phosphatases as poten- 
tial targets, the question of how to design specific 
inhibitors arises. From a mechanistic and structural stand- 
point, phosphatases are an enormously diverse group of 
enzymes [3]. If we add the equally diverse family of phos- 
phodiesterases to the list of enzymes that might be useful 
targets, it becomes clear that new strategies for inhibitor 
design are needed. This is a huge and largely unexplored 
area. In this review, we summarize some of the most 
recent work on the rational design and development of 
phosphatase inhibitors and suggest possible new direc- 
tions for the development of additional types of inhibitors 
for both phosphatases and phosphodiesterases. 
Motii for phosphatase inhibition 
The development of new phosphatase inhibitors would be 
facilitated if we could identify generic inhibitory ‘motifs’ 
that would be a suitable starting point for studying struc- 
ture-activity relationships or to guide the design of a com- 
binatorial chemistry library. For long-standing problems, 
such as the development of protease inhibitors, medicinal 
chemists have a veritable arsenal of such motifs available in 
the form of affinity reagents, mechanism-based inhibitors, 
and transition-state analogs. Unfortunately, few such inhi- 
bitory motifs are available for phosphatases. To complicate 
matters, many phosphatases interact largely, or even solely, 
with the phosphoryl portion of the phosphate ester. For 
example, alkaline phosphatase binds inorganic phosphate 
more tightly than it does phosphate monoesters. Indeed, 
inorganic oxoanions such as vanadate, arsenate, tungstate 
and molybdate are potent nonselective inhibitors of almost 
all phosphatases [4,5]. Unfortunately, compounds such 
as these afford little inspiration for the design of new 
inhibitor motifs that might ultimately serve as the basis for 
drug design. 
Despite this generally unsatisfactory state of affairs, some 
inroads into the development of phosphatase inhibitors 
have been made over the past few years. Figure 1 outlines 
some newly discovered motifs,for phosphatase inhibition. 
Building combinatorial libraries of small molecules or pep- 
tidomimetics around these motifs should yield inhibitors of 
even higher potency and selectivity. Moreover, a number 
of these inhibitor types are already sufficiently developed 
to function as useful research tools. 
Competitive inhibitors 
Metallophosphatase inhibitors 
Approximately half of all phosphatases, as well as a substan- 
tial number of phosphodiesterases and triesterases, contain 
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Some recently developed motifs for phosphatase inhibitors. X, Cl or Br; LG, leaving group. 
active-site metal ions that are essential for catalysis. Com- 
pounds that incorporate an extra metal-binding ligand have 
been shown to be very effective inhibitors of metallopro- 
teases such as the angiotensin converting enzyme [6]. Sur- 
prisingly, until recently no one had designed phosphatase 
inhibitors that used this strategy, although the naturally 
occurring phosphatase inhibitor endothall may use this 
mechanism 171. Figure 2 shows a number of very simple 
compounds that inhibit metalloproteases (81. All these com- 
pounds bear a pendant group that is capable of ligating to 
an active-site metal. These compounds display a great 
range of potencies. For example the aromatic thiol (com- 
pound 11) is the most potent small molecule inhibitor of 
alkaline phosphatase that is known, with a ki of -200 nM 
(81. But compounds such as 12 and 14 have relatively 
modest, though still significant, inhibitory activity. 
Figure 2 
Structures of seven very simple 
metallophosphatase inhibitors. 
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Figure 4 
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The crystal structure of the active site of E. co/i alkaline phosphatase 
with inhibitor 12 bound. Note that the inhibitor makes three contacts to 
the active-site metals. 
A crystal structure of compound 12 bound to alkaline 
phosphatase has been determined (T.S.W., J.K.M., B.S., 
K.M.H. and E.R.K., unpublished observations). In this 
structure (Figure 3), it can be seen clearly that the 
pendant group of the inhibitor reaches around to engage 
in an extra contact to an active-site zinc. In a sense, this 
inhibitor mimics the binding of a high-energy phospho- 
rane intermediate or transition state, as these species prob- 
ably make three zinc ion contacts (Figure 4b), while the 
bound substrate makes only two (Figure 4a). 
This simple notion for inhibitor design can probably be 
exploited for the design of both potent and selective phos- 
phatase and phosphodiesterase inhibitors. Given the 
ubiquitous nature of alkaline phosphatase, inhibitors such 
as compound 11 should be quite useful as tools for study- 
ing phenomena associated with protein/small-molecule 
phosphorylation. In this context, it is worth noting that 
many of these compounds exhibit surprising selectivity. 
For example, while compound 11 is a very potent inhibitor 
of alkaline phosphatase, it is a fairly poor inhibitor of 
purple acid-phosphatase, another phosphatase that uses a 
zinc-containing metal dyad. 
Phosphotyrosine-phosphatase inhibitors 
Compounds 6 and 7 (Figure 1) represent two different 
competitive inhibitor types for phosphotyrosine phos- 
phatases (PTPases). Inhibitor 6 is based on a cinnamic 
acid motif that was appended to various peptide-like 
pieces using combinatorial approaches [9]. The result of 
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The presumed binding mode of (a) phosphatase monoesters and 
(b) presumed reaction transition states of metallophosphatases. 
Nu is an active site nucleophile, or a metal-bound water molecule. 
this exercise was the development of some fairly potent 
PTPase inhibitors that showed some level of selectivity 
even against closely related phosphatases. Compound 7 is 
based on the difluorophosphonate motif. Inclusion of a 
phosphonate analog of phosphotyrosine into a suitable 
peptide yields inhibitors that can be quite potent [lo]. 
Affinity reagents 
Two newly developed classes of affinity reagents are the 
cl-halophosphonates [l l] and the cr-ketophosphonates 
(T.S.W., W.P. Taylor, and J. Roestamadji, unpublished 
observations). To date, little is known about the selectivity 
and mechanism of action of the a-ketophosphonates, 
although they appear to be potent in the low micromolar 
range and to show time-dependent PTPase inactivation. 
The a-halophosphonates have been studied more exten- 
sively, however. These inhibitors appear to be highly spe- 
cific for PTPases and do not inactivate other phosphatases 
or even react with strong nucleophiles such as azide, 
hydroxylamine or thiolates. The cl-halophosphanates are 
easily prepared in three steps from the corresponding alde- 
hydes. Given their selectivity and ease of preparation, 
these inhibitors show great promise for use in developing a 
new generation of PTPase inhibitors. 
Mechanism-based inhibitors 
There is currently only one general type of mechanism- 
based inhibitor of a phosphatase [l&13]. Compound 4 
(Figure 1) is an example of such an inhibitor. These 
inhibitors are potent against both prostatic acid phos- 
phatase and phosphotyrosine phosphatases. Figure 5 
shows the probable mechanism by which these com- 
pounds inactivate phosphatases. Cleavage of the phos- 
phate ester leads to the rapid elimination of a fluoride ion 
to give a quinone methide. This alkylating agent must 
react with an active site nucleophile prior to its release 
from the active site. Although some very potent Phos- 
phatase inhibitors [14] have been developed using this 
motif, it seems unlikely that this methodology will be 
useful for the development of therapeutic agents. This is 
because nonselective phosphatases are present that 
would react with these inhibitors before they have an 
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The probable mechanism for the inactivation of 
phosphatases by compound 4. B is an active- 
site base and Nu is an active-site nucleophile. 
opportunity to reach their site of action. These phos- 
phatase inhibitors do, however, represent a useful strat- 
egy for the pursuit of phosphodiesterase inhibitors and a 
ribonuclease A inhibitor has been developed using this 
motif [15]. 
Pempeetlvw . 
In the past five years a number of advances in inhibitor 
design have opened the doors for the development of a 
new generation of phosphatase inhibitors. These advances, 
based largely on the rational design of new molecular 
motifs, provide starting points for combinatorial chemistry 
and structure-based design. It seems likely that the next 
five years will see the advent of selective and potent mol- 
ecules based on these inhibitory motifs and the application 
of these compounds to the study of signal transduction 
pathways and the development of new therapeutic agents. 
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